Please use this identifier to cite or link to this item:
Author(s): Serrano, F.
Lima, M. L.
Lopes, C.
Almeida, J. P.
Branco, J.
Date: 2011
Title: Factor V Leiden and Prothrombin G20210A in Portuguese women with recurrent miscarriage: is it worthwhile to investigate?
Volume: 284
Number: 5
Pages: 1127-1132
ISSN: 0932-0067
Keywords: Factor V Leiden
Prothrombin G20210A
Recurrent miscarriage
Abstract: Objective: To compare the prevalence of factor V Leiden (FVL) and prothrombin (PT) G20210A mutations in Portuguese women with unexplained recurrent miscarriage (RM) and a control group of parous women. Materials and methods: FVL and PT G20210A analysis were carried out in 100 women with three or more consecutive miscarriages and 100 controls with no history of pregnancy losses. Secondary analysis was made regarding gestational age at miscarriage (embryonic and fetal losses). Results: Overall, the prevalence of FVL and PT G20210A was similar in women with RM (5 and 3%) compared with controls (5 and 1%) OR 1.36 (CI 95% 0.45-4.08). In RM embryonic subgroup, PT G20210A was observed in 1.3% of women and FVL prevalence (2.6%) was inclusively lesser than that of controls. Both polymorphisms were more prevalent in women with fetal losses than in controls, although statistical significance was not reached due to the small size of the >10 weeks' subgroup. Conclusion: These data indicate that neither FVL nor PT G20210A is associated with RM prior to 10 weeks of gestation. Therefore, its screening is not indicated as an initial approach in Portuguese women with embryonic RM and negative personal thromboembolic history
Peerreviewed: Sim
Access type: Open Access
Appears in Collections:CIS-RI - Artigos em revistas científicas internacionais com arbitragem científica

Files in This Item:
File Description SizeFormat 
post_print_Arch_Gyn_Obst_1834.pdf180,79 kBAdobe PDFView/Open

FacebookTwitterDeliciousLinkedInDiggGoogle BookmarksMySpaceOrkut
Formato BibTex mendeley Endnote Logotipo do DeGóis Logotipo do Orcid 

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.